'India has intellectual power to be a leader in biomedical innovation,' says Bayer AG

Bayer's CEO Bill Anderson believes India can become a top pharmaceutical market. He highlights the need for supportive policy frameworks, including stronger intellectual property protection. This will attract investment in cutting-edge drugs. India's young population and technological leadership offer significant opportunities. Bayer is investing in innovation centers in Bengaluru, leveraging Indian talent for global missions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kN8cZl1
via IFTTT

Read More

India warns drugmakers against direct or surrogate weight-loss drug and obesity ads

India's drug regulator has issued a stern warning to pharmaceutical companies. Direct or indirect advertising of weight-loss medicines is now prohibited. Obesity awareness campaigns that promote prescription drugs are also under scrutiny. This move comes as global and domestic companies vie for a share of India's growing obesity drug market. The regulator emphasizes that misleading promotions will face action.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Qvqk8LB
via IFTTT

Read More

India medical device shortage: Polypropylene price surge threatens syringes, IV bags amid Iran war

India's medical devices industry faces a polypropylene shortage due to the Iran war, causing a sharp price increase of over Rs 55 per kg. This surge, coupled with a deepening gas supply crisis impacting syringe production, threatens small and medium enterprises and overall healthcare delivery.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jPJiAtX
via IFTTT

Read More

Govt cautions pharma cos against surrogate ads for promoting GLP-1 drugs

Weight loss drug risks: The government has warned of strict regulatory action against those found using surrogate advertising to promote GLP-1 drugs. "A detailed advisory on the use of GLP-1 drugs is expected to be released in the next few days," sources told ET.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9AnrLdw
via IFTTT

Read More

Decoding the antibiotic resistance crisis: How everyday habits can save our strongest medicines

Antibiotics are losing their power as germs grow stronger, a crisis fueled by everyday misuse. Experts urge parents to rethink treating minor ailments and fevers without medical advice. Preventing infections through simple hygiene practices like handwashing and sanitizing surfaces, summarized by the S.H.A.K.E. formula, is crucial to preserving these life-saving medicines for future generations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3diYcxA
via IFTTT

Read More

Raw nerve: Drugs may get costlier as prices of ingredients surge 30%

India's medicine prices are poised for a sharp increase due to a 30% surge in raw material costs, driven by container ship scarcity following the Iran war. This scarcity is hindering the movement of crucial ingredients from China, impacting local manufacturing and potentially forcing producers to pass on higher expenses to consumers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tk2Gyhv
via IFTTT

Read More

India's exports of active pharma ingredients at Rs 41,500 cr surpassed imports in FY25

With API exports hitting an impressive Rs 41,500 crore last fiscal year, India has outperformed its imports of Rs 39,215 crore. The government is pushing for a self-reliant economy via the Production Linked Incentive scheme, strategically aimed at cutting down import connections, notably with China.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qGlBJYv
via IFTTT

Read More